Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;31(6):412-22.
doi: 10.1007/s00292-010-1352-8.

[Differential diagnostics of hereditary colorectal cancer syndromes. The role of pathology]

[Article in German]
Affiliations

[Differential diagnostics of hereditary colorectal cancer syndromes. The role of pathology]

[Article in German]
J Rüschoff et al. Pathologe. 2010 Oct.

Abstract

One third of colorectal carcinomas (CRC) show familial clustering of which about 5% have a monogenetic trait. Distinction between disease with and without polyposis, tumor histology and tumor spectrum in a given patient are all of diagnostic relevance. Familial adenomatous polyposis (FAP) underlies approximately 1% of CRC characterized by rapidly forming (>100) adenomas. In contrast to these about 2%-3% of CRC have a hereditary background without polyposis (HNPCC). This is the only hereditary tumour syndrome to date for which a tissue-based molecular screening test is available. Accordingly, expression analysis of mismatch repair genes (MSH2, MSH6 and MLH1, PMS2) is performed first. In the case of an equivocal result with no complete loss of expression testing of microsatellite instability (MSI) is added. In contrast to the other diseases MYH-associated polyposis (MAP) follows a recessive trait with polyp numbers usually between 15-30 adenomas and should be distinguished from attenuated forms of FAP with <100 polyps in the differential diagnosis. In the case of suspected familial cancer syndrome genetic counseling is warranted in order to decide ultimately whether there is an indication for genetic testing (evidence of a germ-line mutation).

PubMed Disclaimer

References

    1. Am J Pathol. 1998 Dec;153(6):1977-84 - PubMed
    1. N Engl J Med. 2003 Feb 27;348(9):791-9 - PubMed
    1. J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 - PubMed
    1. Cancer Immunol Immunother. 2009 Jan;58(1):135-44 - PubMed
    1. Int J Cancer. 2010 Dec 1;127(11):2678-84 - PubMed

Publication types

MeSH terms